MedTrace Logo

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

NCT06208748 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-31

No results posted yet for this study

Summary

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.

Conditions

Interventions

DRUG

Bezuclastinib in combination with sunitinib

Bezuclastinib in combination with sunitinib (sutent)

Sponsors & Collaborators

  • Cogent Biosciences, Inc.

    collaborator INDUSTRY

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • The Life Raft Group

    collaborator UNKNOWN

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Candace Haddox, MD · Dana-Farber Cancer Institute

  • Andrew Wagner, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208748 on ClinicalTrials.gov